Gangliosides for acute ischaemic stroke

Candelise, Livia; Ciccone, Alfonso

doi:10.1002/14651858.cd000094

Cited by 38 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…566 -569 A systematic review of this agent did not demonstrate any benefit from treatment. 570 Piracetam also has been tested in several clinical trials, with mixed results. [571][572][573][574] Reviews of the medication also have reached differing conclusions; although the agent may be effective in some patients with ischemic stroke, there may be a trend for increased risk of death among patients treated with piracetam.…”

Section: Neuroprotective Agentsmentioning

confidence: 99%

Guidelines for the Early Management of Adults With Ischemic Stroke

Adams¹,

Zoppo²,

Alberts³

et al. 2007

Circulation

1,058

745

View full text Add to dashboard Cite

Purpose-Our goal is to provide an overview of the current evidence about components of the evaluation and treatment of adults with acute ischemic stroke. The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included. Key Words: AHA Scientific Statements Ⅲ emergency medical services Ⅲ stroke Ⅲ acute cerebral infarction Ⅲ tissue plasminogen activator †Deceased. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. Methods-Members

show abstract

Section: Neuroprotective Agentsmentioning

confidence: 99%

Guidelines for the Early Management of Adults With Ischemic Stroke

Adams¹,

Zoppo²,

Alberts³

et al. 2007

Circulation

1,058

745

View full text Add to dashboard Cite

show abstract

“…788 Several trials of GM1-ganglioside, which also may stabilize membranes, have not demonstrated improved outcomes with treatment, [789][790][791][792] and a systematic review of this agent did not demonstrate any benefit from treatment. 793 In addition to their low-density lipoprotein cholesterol-lowering effects, statins, or HMG-CoA reductase inhibitors, exert acute neuroprotective properties, including beneficial effects on endothelial function, cerebral blood flow, and inflammation. Formal dose-escalation trials are under way to evaluate statins as acute neuroprotective agents.…”

Section: -784mentioning

confidence: 99%

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Jauch¹,

Saver²,

Adams³

et al. 2013

Stroke

5,331

1,801

View full text Add to dashboard Cite

Background and Purpose-The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audiences are prehospital care providers, physicians, allied health professionals, and hospital administrators responsible for the care of acute ischemic stroke patients within the first 48 hours from stroke onset. These guidelines supersede the prior 2007 guidelines and 2009 updates. Methods-Members of the writing committee were appointed by the American Stroke Association Stroke Council's Scientific Statement Oversight Committee, representing various areas of medical expertise. Strict adherence to the American Heart Association conflict of interest policy was maintained throughout the consensus process. Panel members were assigned topics relevant to their areas of expertise, reviewed the stroke literature with emphasis on publications since the prior guidelines, and drafted recommendations in accordance with the American Heart Association Stroke Council's Level of Evidence grading algorithm. Results-The goal of these guidelines is to limit the morbidity and mortality associated with stroke. The guidelines support the overarching concept of stroke systems of care and detail aspects of stroke care from patient recognition; emergency medical services activation, transport, and triage; through the initial hours in the emergency department and stroke unit. The guideline discusses early stroke evaluation and general medical care, as well as ischemic stroke, specific interventions such as reperfusion strategies, and general physiological optimization for cerebral resuscitation. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. Guidelines for the Early Management of PatientsThis statement was approved by the American Heart Association Science Advisory and Coordinating Committee on December 12, 2012. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.The Executive Summary is available as an online-only Data Supplement with this article at http://stroke.ahajournals.org/lookup/suppl/ doi:10.1161/STR.0b013e318284056a/-/DC1.The American Heart Association requests that this document be cited as follows: Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; on behalf of the American Heart Association Stroke Council, Council on Cardio...

show abstract

“…With regard to Ca antagonists (mainly studies of nimodipine), 63-65 the efficacy of monosialoganglioside GM1 (not approved in Japan) 66 or piracetam 67 was not demonstrated as drugs for the treatment of acute cerebral infarction (Ia).…”

Section: Notementioning

confidence: 99%